lumacaftor and Alzheimer-Disease

Alzheimer's disease (AD) is a severe neurodegenerative disorder for which identification of differentially expressed genes is one way to find new therapeutic targets. Here, we conducted analysis to identify age-independent, AD-specific genes. We found that the MET, WIF1, and NPTX2 genes are downregulated in AD. WIF1 and MET are implicated in Wnt and MET signaling and regulate GSK3β activity and are thus linked with AD. Importantly, we found that the GMPR gene exhibited a gradual increase in AD progression. A logistic model based on GMPR has good ability to classify AD cases. GMPR's product GMPR1 is in the AMPK and adenosine receptor pathways and is thus associated with Tau phosphorylation in AD. This allows GMPR1 to be a therapeutic target. Therefore, we screened five possible inhibitors to GMPR1 by docking GMPR1 with 1,174 approved drugs. Among them, lumacaftor is ideal. We then tested the effects of lumacaftor on AD model mice. After 20 days of oral administration, we observed that β-Amyloid accumulation was slowed down, and phosphorylation of Tau was almost eliminated in the treated mice. We highlight the elevated expression level of GMPR in AD and propose a therapeutic strategy of inhibiting GMPR1 with lumacaftor.

Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzodioxoles; C-Reactive Protein; Databases, Genetic; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3 beta; GMP Reductase; Mice; Molecular Targeted Therapy; Nerve Tissue Proteins; Phosphorylation; Proto-Oncogene Proteins c-met; Repressor Proteins; tau Proteins; Wnt Signaling Pathway